drugset / Trial / NCT06169072

Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients

NCT06169072 ↗

Phase 2 Recruiting 220 enrolled Vastra Gotaland Region
NaSingle-groupOpen-labelDiagnostic

Summary

The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.

Timeline

Start
2023-01-01
Primary completion
2024-07-01
Completion
2027-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Superparamagnetic Iron Oxide Diagnostic / imaging agent 0.1 ml Inhaled

Indications